Forecast

The analysts' average price target is €19.42 (+72.16%). The median is €19.42 (+72.16%).

Buy	9
Hold	1
Sell	0

News Go to news feed

Candel Therapeutics hits 52-week high at $13.96 and launches phase‑III AURORA study

Candel Therapeutics’ stock rose to a 52‑week high of $13.96 and is currently trading around $13.93, implying a market capitalization of about $1.06 billion. The shares have gained substantially year‑to‑date (roughly +125–132% according to data), and InvestingPro sees the stock near its fair value. Candel has initiated the global phase‑III AURORA study of aglatimagene besadenovec in metastatic non‑small cell lung cancer; analysts raised price targets and reiterated buy ratings. Mark Sims was also appointed chief commercial officer; the company is targeting a Biologics License Application submission for the therapy by the end of 2026. » More on de.investing.com
Candel Therapeutics: positive phase‑3 data on aglatimagene besadenovec and launch of AURORA study

Candel Therapeutics reports pivotal phase‑3 PrTK03 data showing a significant improvement in disease‑free survival for aglatimagene besadenovec in localized prostate cancer. In parallel, the phase‑3 AURORA study was launched. Stifel initiated coverage of the stock with a 'Buy' rating and a $22 price target. » More on finanzen.net
Candel strikes commercialization partnership with Eversana for prostate cancer drug

Candel has agreed a product commercialization deal with Eversana to support the potential U.S. launch of aglatimagene besadenovec. Eversana will provide data analytics, medical affairs, market access and field support; a BLA filing is planned for Q4 2026. According to analysis, Candel has more cash than debt and is continuing to prepare for regulatory review; aglatimagene has Fast Track and RMAT designations but is not yet approved. Analyst consensus is "Strong Buy" with price targets of $7 to $26, the stock was volatile last week and is currently trading at $6.20. » More on de.investing.com

Financials

In the last quarter, CANDEL THERAP.INC. DL-,01 had revenue of €0 and net profit of -€34.09M

(EUR)	Jun 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-34.09M	737.77%
EBITDA	-32.43M	785.18%

Fundamentals

Metric	Value
Market capitalization	€881.56M
Number of shares	73.27M
52-week high/low	€12.08 - €3.75
Dividends	No
Beta	-0.50
P/E ratio	-9.89
PEG ratio	0.12
P/B ratio	8.19
P/S ratio	0.00

Company profile

Candel Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und beschäftigt sich mit der Entwicklung von Immuntherapien für Krebspatienten. Das Unternehmen entwickelt CAN-2409, das sich in klinischen Studien der Phase II zur Behandlung von Bauchspeicheldrüsenkrebs, in klinischen Studien der Phase III zur Behandlung von Prostatakrebs und in klinischen Studien der Phase II zur Behandlung von Lungenkrebs befindet, und hat klinische Studien der Phase Ib/II zur Behandlung von hochgradigen Gliomen abgeschlossen. Das Unternehmen entwickelt außerdem CAN-3110, das sich in klinischen Studien der Phase I zur Behandlung des rezidivierenden Glioblastoms befindet. Das Unternehmen war früher als Advantagene, Inc. bekannt und änderte im November 2020 seinen Namen in Candel Therapeutics, Inc. Das Unternehmen wurde im Jahr 2003 gegründet und hat seinen Sitz in Needham, Massachusetts.

Name	CANDEL THERAP.INC. DL-,01
CEO	Paul-Peter Tak
Headquarters	Needham, ma USA
Website	candeltx.com
Sector	Consumer Staples
Industry	Food Products
IPO	07/27/2021
Employees	55